Asia Pacific Gastric Cancer Diagnostics Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2024 –2030 |
 Tamaño del mercado (año base) |
|
 Tamaño del mercado (año de pronóstico) |
USD 471.25 |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
>Mercado de diagnóstico de cáncer gástrico de Asia y el Pacífico, por tipo de producto (instrumentos, reactivos y consumibles, servicios), tipo de diagnóstico (prueba de confirmación, pruebas de detección de cáncer gástrico/examen físico), grupo de edad (adultos, niños y geriatría), tipo de enfermedad (adenocarcinoma intestinal o difuso, tumor carcinoide, tumor del estroma gastrointestinal (GIST), linfoma gástrico y otros), estadio (estadio 0, estadio I, estadio II, estadio III), género (masculino y femenino), tipo de muestra (sangre, tejido, orina y heces), usuarios finales (laboratorios de diagnóstico, hospitales, institutos de investigación del cáncer, clínicas especializadas en oncología y otros), canal de distribución (licitaciones directas y ventas minoristas): tendencias de la industria y pronóstico hasta 2030.
Análisis y perspectivas del mercado de diagnóstico de cáncer gástrico en Asia y el Pacífico
El aumento de la población geriátrica en Asia y el Pacífico está impulsando el crecimiento de la industria de diagnóstico del cáncer gástrico. La prevalencia de tumores gastrointestinales y linfomas también ha impulsado la demanda de diagnósticos de cáncer gástrico. La principal limitación del mercado es la necesidad de reducir los altos precios asociados con las pruebas de diagnóstico del cáncer para que incluso los países en desarrollo puedan beneficiarse de ellas.
Un gran número de actores del mercado están ofreciendo productos de diagnóstico de cáncer gástrico con innovaciones que allanan el camino para el crecimiento de dicho mercado.
Data Bridge Market Research analiza que se espera que el mercado de diagnóstico de cáncer gástrico de Asia-Pacífico alcance un valor de USD 471,25 millones para 2030, con una CAGR del 10,0 % durante el período de pronóstico. Los reactivos y consumibles representan el segmento de tipo de producto más grande en el mercado debido a la creciente demanda de kits y reactivos, y el aumento de los gastos de salud ha acelerado la demanda de dispositivos médicos inteligentes.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2023 a 2030 |
|
Año base |
2022 |
|
Años históricos |
2021 (Personalizable para 2015-2020) |
|
Unidades cuantitativas |
Ingresos en millones de USD, volúmenes en unidades, precios en USD |
|
Segmentos cubiertos |
Por tipo de producto (instrumentos, reactivos y consumibles, servicios), tipo de diagnóstico (prueba de confirmación, pruebas de detección de cáncer gástrico/examen físico), grupo de edad (adultos, niños y geriatría), tipo de enfermedad (adenocarcinoma intestinal o difuso, tumor carcinoide, tumor del estroma gastrointestinal (GIST), linfoma gástrico y otros), estadio (estadio 0, estadio I, estadio II, estadio III), género (masculino y femenino), tipo de muestra (sangre, tejido, orina y heces), usuarios finales (laboratorios de diagnóstico, hospitales, institutos de investigación del cáncer, clínicas especializadas en oncología y otros), canal de distribución (licitaciones directas y ventas minoristas) |
|
Países cubiertos |
Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas, resto de Asia-Pacífico |
|
Actores del mercado cubiertos |
BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Vela Diagnostics, Abbott, AdvaCare Pharma, MiRXES, Fujirebio (An H.U. Group company), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, DiaSorin S.p.A, Paragon Genomics, Inc., and QIAGEN among others |
Market Definition
Stomach cancer is a type of cancer that starts in the stomach and spreads throughout the body. The stomach is a muscular pouch that lies immediately below the ribs in the upper part of the abdomen. The stomach takes in and holds the food we eat before breaking it down and digesting it. Stomach cancer, commonly referred to as gastric cancer, can occur in any section of the stomach. Stomach cancers develop in the major section of the stomach in most parts of the world (stomach body). Various diagnostic tests used for the diagnosis of cancer include prescreening tests, biopsy, biomarkers, imaging tests, PET/CT scans, and ultrasound among others.
Cancer is caused by uncontrolled, abnormal cell proliferation that has the ability to spread and invade other sections of the body. Changes in the gene cause a single cell or a few cells to expand and replicate, which is when cancer begins. This could lead to the growth of a tumor, which is an abnormal mass of tissue. The creation of cancer cells in the stomach lining is known as gastric cancer or stomach cancer. Diet and stomach disorders are both risk factors for gastric cancer.
Asia-Pacific Gastric Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increase in incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma
According to a report published in Clinical Medicine, gastric cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide in 2020. In 2020, an estimated 1.1 million cases (720,000 males and 370,000 females) of gastric cancer were diagnosed worldwide. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Every year, about a million new instances of stomach cancer are diagnosed around the world.
It is projected that the incidence of gastric cancer will rise, due to to aging and increasing population, lifestyle, and socioeconomic change. Striking variations in race, sociocultural norms, behaviors, and dietary trends are reflected in the burden and distribution of cancer in different regions across the globe.
Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics. Thus the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma are expected to drive the growth of the Asia-Pacific gastric cancer diagnostics market.
- Rise in alcohol consumption and surge in smoking
Los datos epidemiológicos, clínicos y de laboratorio indican que existe una relación conductual entre el consumo de cigarrillos y el consumo de alcohol. El consumo combinado de cigarrillos y alcohol plantea problemas de salud que se suman a los que plantea el tabaquismo por sí solo, por lo que representa un grave problema de salud pública que justifica una mayor investigación.
Cada vez que un fumador inhala un cigarrillo encendido se produce una reacción química en cadena, que produce docenas de sustancias químicas peligrosas. El humo del cigarrillo contiene sustancias que se inhalan a través de los labios, la lengua y la boca, bajan por la garganta y llegan a los pulmones, lo que produce inflamación y expone esas partes del cuerpo a sustancias químicas que provocan cáncer.
Por lo tanto, se espera que el aumento del consumo de alcohol y el incremento del tabaquismo impulsen el crecimiento del mercado del cáncer gástrico en Asia y el Pacífico.
Oportunidad
-
Aumento de la adopción de sistemas automatizados
El cáncer es una enfermedad sistémica y en red. Esto indica que en una célula cancerosa, ciertos genes relacionados con la red dejan de funcionar correctamente. Las interacciones complejas en dichas redes genéticas deben abordarse en el tratamiento del cáncer. Los algoritmos de inteligencia artificial (IA), en particular, han evolucionado rápidamente, lo que se refleja en el progreso de la oncología.
El aprendizaje automático y las redes neuronales están adquiriendo cada vez mayor importancia en la oncología de precisión y la medicina sistémica. La combinación de datos de imágenes con datos clínicos y moleculares abre un mundo de posibilidades. La radiogenómica, por ejemplo, es un nuevo campo centrado en el procesamiento de datos multidimensionales. También puede beneficiarse de los avances de la IA.
Por tanto, la creciente adopción de sistemas automatizados actúa como una oportunidad para el crecimiento de este mercado.
Restricción/Desafío
- Falta de apoyo financiero suficiente de las pólizas de seguro de salud
Para alcanzar sus objetivos, los sistemas de salud necesitan recursos financieros. Los recursos humanos, la atención hospitalaria y los medicamentos son los aspectos más costosos de la mayoría de los sistemas de atención sanitaria. En la mayoría de los países tropicales, la atención sanitaria se financia mediante una combinación de gasto público, privado (principalmente de bolsillo) y ayuda internacional.
La financiación de la atención sanitaria sigue siendo una preocupación fundamental para los países de ingresos bajos y medianos bajos. Muchos países de ingresos medianos altos de América Latina, África y Asia han logrado establecer mecanismos de financiación de la salud que cubren a grandes segmentos de su población. Estas medidas permiten el acceso a la atención sanitaria y, al mismo tiempo, protegen a las personas de las deudas catastróficas que se derivan de ese acceso. Por otra parte, la financiación es un obstáculo importante para la prestación de servicios de salud en los países de ingresos bajos (la mayoría de los cuales se encuentran en el África subsahariana).
Por lo tanto, la falta de apoyo financiero suficiente de las pólizas de seguro de salud actúa como un freno al crecimiento del mercado.
Acontecimientos recientes
- En octubre de 2022, General Electric Company colaboró con varios institutos de investigación como los Hospitales de la Universidad de Cambridge, Sophia Genetics y anteriormente con Optellum para utilizar datos de imágenes en colaboración con inteligencia artificial. Esto ayudará a reducir el tiempo de diagnóstico de varios tipos de cáncer y ayudará a brindar atención personalizada a los pacientes. Esto ha ayudado a la empresa a ampliar sus horizontes en el diagnóstico del cáncer.
- En marzo de 2020, Thermo Fisher Scientific Inc. anunció que adquiriría QIAGEN, una empresa holandesa de diagnóstico molecular y atención médica. Esta adquisición por parte de la empresa aumentará su cartera de productos en el mercado, lo que generará un aumento de los ingresos en el futuro.
Alcance del mercado de diagnóstico de cáncer gástrico en Asia y el Pacífico
El mercado de diagnóstico de cáncer gástrico de Asia-Pacífico está segmentado en nueve segmentos notables según el tipo de producto, el tipo de diagnóstico, el grupo de edad, el tipo de enfermedad, la etapa, el género, la muestra, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
TIPO DE PRODUCTO
- Instrumentos
- Reactivos y consumibles
- Servicios
Según el tipo de producto, el mercado se segmenta en instrumentos, reactivos y consumibles y servicios.
TIPO DE DIAGNÓSTICO
- Prueba confirmatoria
- Pruebas de detección de cáncer gástrico/examen físico
Según el tipo de diagnóstico, el mercado está segmentado en pruebas de detección de cáncer gástrico/examen físico y pruebas confirmatorias.
GRUPO DE EDAD
- Adulto
- Pediátrico
- Geriatría
Según el grupo de edad, el mercado se segmenta en adultos, pediátricos y geriátricos.
TIPO
- Adenocarcinoma intestinal o difuso
- Tumor carcinoide
- Tumor del estroma gastrointestinal (GIST)
- Linfoma gástrico
- Otros
Según el tipo, el mercado está segmentado en adenocarcinoma intestinal o difuso, tumor carcinoide, tumor del estroma gastrointestinal (GIST), linfoma gástrico y otros.
ESCENARIO
- Etapa 0
- Etapa I
- Estadio II
- Estadio III
En función de la etapa, el mercado se segmenta en etapa 0, etapa I, etapa II y etapa III.
GÉNERO
- Masculino
- Femenino
En función del género, el mercado está segmentado en masculino y femenino.
TIPO DE MUESTRA
- Sangre
- Tejido
- Orina
- Heces
Según el tipo de muestra, el mercado se segmenta en sangre, tejido, orina y heces.
USUARIO FINAL
- Laboratorios de diagnóstico
- Hospitales
- Institutos de investigación del cáncer
- Clínicas especializadas en oncología
- Otros
Sobre la base de los usuarios finales, el mercado está segmentado en laboratorios de diagnóstico, hospitales, institutos de investigación del cáncer, clínicas especializadas en oncología y otros.
CANAL DE DISTRIBUCIÓN
- Licitaciones directas
- Ventas al por menor
Sobre la base del canal de distribución, el mercado está segmentado en licitación directa y ventas minoristas.
Análisis y perspectivas regionales del mercado de diagnóstico de cáncer gástrico en Asia y el Pacífico
El mercado de diagnóstico de cáncer gástrico de Asia y el Pacífico está segmentado en nueve segmentos notables según el tipo de producto, el tipo de diagnóstico, el grupo etario, el tipo de enfermedad, la etapa, el género, la muestra, el usuario final y el canal de distribución.
Los países cubiertos en este informe de mercado son Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas y el resto de Asia-Pacífico.
Se espera que Corea del Sur domine el mercado de diagnóstico de cáncer gástrico en Asia-Pacífico debido al aumento de las inversiones en I+D de dispositivos médicos e investigación en ciencias biológicas.
La sección de países del informe también proporciona factores individuales que impactan en el mercado y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Asia-Pacífico y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, y el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.
Análisis del panorama competitivo y de la cuota de mercado de los diagnósticos de cáncer gástrico
El panorama competitivo del mercado de diagnóstico de cáncer gástrico de Asia-Pacífico proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en I+D, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las aprobaciones de productos, la amplitud y la extensión de los productos, el dominio de las aplicaciones, la curva de vida del tipo de producto. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa en el mercado de diagnóstico de cáncer gástrico de Asia-Pacífico.
Algunos de los principales actores que operan en el mercado son BIOMÉRIEUX, Myriad Genetics, Inc., ACON Laboratories, Inc., Vela Diagnostics, Abbott, AdvaCare Pharma, MiRXES, Fujirebio (una empresa del grupo HU), Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Endofotonics Pte Ltd, Biohit Oyj, DiaSorin SpA, Paragon Genomics, Inc. y QIAGEN, entre otros.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 EPIDEMIOLOGY
4.4 BRAND ANALYSIS
4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET
4.6 INDUSTRY INSIGHTS:
5 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY
5.1 ASIA-PACIFIC
5.1.1 REGULATORY SCENARIO IN AUSTRALIA-
5.1.2 REGULATORY SCENARIO IN JAPAN
5.1.3 REGULATORY SCENARIO IN CHINA
5.1.4 REGULATORY SCENARIO IN SINGAPORE-
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA
6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
6.1.3 INCREASE IN THE GERIATRIC POPULATION
6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS
6.2 RESTRAINTS
6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST
6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES
6.3 OPPORTUNITIES
6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS
6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS
6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES
6.4.2 LIMITATIONS OF RADIATION TESTS
7 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 REAGENTS & CONSUMABLES
7.2.1 KITS
7.2.1.1 DNA POLYMERASE KITS
7.2.1.2 PCR KITS
7.2.1.3 NUCLEIC ACID ISOLATION KITS
7.2.1.4 OTHERS
7.2.2 REAGENTS
7.2.2.1 ASSAYS
7.2.2.2 BUFFERS
7.2.2.3 PRIMERS
7.2.2.4 OTHERS
7.3 INSTRUMENTS
7.4 SERVICES
8 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE
8.1 OVERVIEW
8.2 CONFIRMATORY TEST
8.2.1 IMAGING TESTS
8.2.1.1 PET SCAN/CT SCAN
8.2.1.2 CT SCAN
8.2.1.3 ULTRASOUND
8.2.1.4 MRI
8.2.1.5 X-RAY
8.2.2 BIOMARKER
8.2.2.1 DNA BIOMARKER
8.2.2.2 RNA BIOMARKER
8.2.2.3 PROTEIN BIOMARKER
8.2.3 BIOPSY
8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM
9 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP
9.1 OVERVIEW
9.2 GERIATRICS
9.3 ADULT
9.4 PEDIATRIC
10 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA
10.3 CARCINOID TUMOR
10.4 GASTROINTESTINAL STROMAL TUMOR
10.5 GASTRIC LYMPHOMA
10.6 OTHERS
11 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE
11.1 OVERVIEW
11.2 STAGE I
11.2.1 STAGE IA
11.2.2 STAGE IB
11.3 STAGE II
11.3.1 STAGE IIA
11.3.2 STAGE IIB
11.4 STAGE III
11.4.1 STAGE IIIA
11.4.2 STAGE IIIB
11.4.3 STAGE IIIC
11.5 STAGE 0
12 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE
13.1 OVERVIEW
13.2 STOOL
13.3 TISSUE
13.4 BLOOD
13.5 URINE
14 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC LABORATORIES
14.4 CANCER RESEARCH INSTITUTES
14.5 ONCOLOGY SPECIALTY CLINICS
14.6 OTHERS
15 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDERS
15.3 RETAIL SALES
16 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION
16.1 ASIA-PACIFIC
16.1.1 SOUTH KOREA
16.1.2 JAPAN
16.1.3 CHINA
16.1.4 AUSTRALIA
16.1.5 SINGAPORE
16.1.6 INDIA
16.1.7 THAILAND
16.1.8 MALAYSIA
16.1.9 INDONESIA
16.1.10 PHILIPPINES
16.1.11 REST OF ASIA-PACIFIC
17 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 F. HOFFMANN-LA ROCHE LTD
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 GENERAL ELECTRIC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 ABBOTT
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 QIAGEN
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 MYRIAD GENETICS, INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ACON LABORATORIES, INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 ADVACARE PHARMA
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 AGILENT TECHNOLOGIES, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 BIOMÉRIEUX
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BIOCEPT, INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 BIOHIT OYJ
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 DIASORIN S.P.A
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 ENDOFOTONICS PTE LTD
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 FOUNDATION MEDICINE, INC.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 FUJIREBIO (AN H.U. GROUP COMPANY)
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 MIRXES PTE LTD.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 PARAGON GENOMICS, INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 TECO DIAGNOSTICS
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 THERMO FISHER SCIENTIFIC INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 VELA DIAGNOSTICS
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tablas
TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE
TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-
TABLE 3 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 ASIA PACIFIC REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 ASIA PACIFIC REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 ASIA PACIFIC KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 ASIA PACIFIC REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 ASIA PACIFIC INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 ASIA PACIFIC SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 11 ASIA PACIFIC CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 ASIA PACIFIC CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 13 ASIA PACIFIC IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 14 ASIA PACIFIC BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 15 ASIA PACIFIC GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 17 ASIA PACIFIC GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 ASIA PACIFIC ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 ASIA PACIFIC PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 21 ASIA PACIFIC INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 ASIA PACIFIC CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 ASIA PACIFIC GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 ASIA PACIFIC GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 ASIA PACIFIC OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 27 ASIA PACIFIC STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 ASIA PACIFIC STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 29 ASIA PACIFIC STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 ASIA PACIFIC STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 31 ASIA PACIFIC STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 ASIA PACIFIC STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 33 ASIA PACIFIC STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 35 ASIA PACIFIC MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 ASIA PACIFIC FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 38 ASIA PACIFIC STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 ASIA PACIFIC TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 ASIA PACIFIC BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 ASIA PACIFIC URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 43 ASIA PACIFIC HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 ASIA PACIFIC DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 ASIA PACIFIC ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 ASIA PACIFIC OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 49 ASIA PACIFIC DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 ASIA PACIFIC RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 52 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 ASIA-PACIFIC REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 ASIA-PACIFIC KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 ASIA-PACIFIC REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 57 ASIA-PACIFIC CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 58 ASIA-PACIFIC BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 59 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 60 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 61 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 62 ASIA-PACIFIC STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 63 ASIA-PACIFIC STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 64 ASIA-PACIFIC STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 65 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 66 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 67 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 68 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 69 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 SOUTH KOREA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 SOUTH KOREA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 SOUTH KOREA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 74 SOUTH KOREA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 75 SOUTH KOREA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 76 SOUTH KOREA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 77 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 78 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 79 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 80 SOUTH KOREA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 81 SOUTH KOREA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 82 SOUTH KOREA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 83 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 84 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 85 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 86 SOUTH KOREA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 87 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 JAPAN REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 JAPAN KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 JAPAN REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 92 JAPAN CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 93 JAPAN IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 94 JAPAN BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 95 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 96 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 97 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 98 JAPAN STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 99 JAPAN STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 100 JAPAN STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 101 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 102 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 103 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 104 JAPAN GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 105 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 CHINA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 CHINA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 CHINA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 110 CHINA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 111 CHINA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 112 CHINA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 113 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 114 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 115 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 116 CHINA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 117 CHINA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 118 CHINA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 119 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 120 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 121 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 122 CHINA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 123 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 124 AUSTRALIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 AUSTRALIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 126 AUSTRALIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 127 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 128 AUSTRALIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 129 AUSTRALIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 130 AUSTRALIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 131 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 132 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 133 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 134 AUSTRALIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 135 AUSTRALIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 136 AUSTRALIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 137 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 138 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 139 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 140 AUSTRALIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 141 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 142 SINGAPORE REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 SINGAPORE KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 144 SINGAPORE REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 145 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 146 SINGAPORE CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 147 SINGAPORE IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 148 SINGAPORE BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 149 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 150 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 151 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 152 SINGAPORE STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 153 SINGAPORE STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 154 SINGAPORE STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 155 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 156 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 157 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 158 SINGAPORE GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 159 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 160 INDIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 INDIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 162 INDIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 163 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 164 INDIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 165 INDIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 166 INDIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 167 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 168 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 169 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 170 INDIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 171 INDIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 172 INDIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 173 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 174 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 175 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 176 INDIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 177 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 178 THAILAND REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 179 THAILAND KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 180 THAILAND REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 181 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 182 THAILAND CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 183 THAILAND IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 184 THAILAND BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 185 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 186 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 187 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 188 THAILAND STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 189 THAILAND STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 190 THAILAND STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 191 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 192 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 193 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 194 THAILAND GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 195 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 196 MALAYSIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 197 MALAYSIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 198 MALAYSIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 199 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 200 MALAYSIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 201 MALAYSIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 202 MALAYSIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 203 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 204 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 205 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 206 MALAYSIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 207 MALAYSIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 208 MALAYSIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 209 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 210 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 211 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 212 MALAYSIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 213 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 214 INDONESIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 215 INDONESIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 216 INDONESIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 217 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 218 INDONESIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 219 INDONESIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 220 INDONESIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 221 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 222 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 223 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 224 INDONESIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 225 INDONESIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 226 INDONESIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 227 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 228 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 229 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 230 INDONESIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 231 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 232 PHILIPPINES REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 233 PHILIPPINES KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 234 PHILIPPINES REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 235 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 236 PHILIPPINES CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 237 PHILIPPINES IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 238 PHILIPPINES BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 239 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 240 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 241 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 242 PHILIPPINES STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 243 PHILIPPINES STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 244 PHILIPPINES STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 245 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 246 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 247 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 248 PHILIPPINES GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 249 REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Lista de figuras
FIGURE 1 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: ASIA PACIFIC VS. REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: MARKET END COVERAGE GRID
FIGURE 11 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA IS EXPECTED TO DRIVE THE ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 13 REAGENTS AND CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, OF THE ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET
FIGURE 15 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 16 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 17 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 18 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2022
FIGURE 20 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)
FIGURE 21 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, CAGR (2023-2030)
FIGURE 22 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 24 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 25 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 26 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2022
FIGURE 28 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2023-2030 (USD MILLION)
FIGURE 29 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, CAGR (2023-2030)
FIGURE 30 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2022
FIGURE 32 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2023-2030 (USD MILLION)
FIGURE 33 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2023-2030)
FIGURE 34 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 36 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 37 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2022
FIGURE 40 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)
FIGURE 41 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2023-2030)
FIGURE 42 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 43 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 44 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 45 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 46 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 48 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 49 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 50 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 52 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 53 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 ASIA-PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 56 ASIA PACIFIC GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
